Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $531K rose 10520.0% year over year, ahead of the +71.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 70.7% from the prior quarter. Over 3 fiscal years it compounded at +89.7% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +10520.0% holds above the trailing-twelve-month pace of +71.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 270.79M USD
- Year-over-year change
- +22.2%
- 3-year CAGR
- +89.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 270.79M | +22.2% |
| FY2024 | 2024-12-31 | 221.63M | +52.7% |
| FY2023 | 2023-12-31 | 145.14M | +265.7% |
| FY2022 | 2022-12-31 | 39.69M | — |
Financing Cash Flow vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 financing cash flow of $271.31M is the 4th largest of the 10 companies compared; the peer median is $112.79M.
- Its year-over-year change of +71.7% is the 7th highest of 9, against a peer median of +258.8%.
- Financing cash flow amounts to 1356.6% of revenue for RAPP, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +505.2% | +306.4% | — | |
| LTM Mar 2026 | $463.02M | +23881.0% | +141.9% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $396.39M | — | +136.2% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.31M | +71.7% | +89.7% | 1356.6% |
| LTM Mar 2026 | $165.89M | +1517.0% | +11.1% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $112.79M | +3.6% | — | — |
| LTM Jun 2026 | $88.79M | -18.1% | -29.1% | 11.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $87.96M | +345.2% | -12.7% | — |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Mar 2026 | $35.04M | +172.3% | +87.5% | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $112.79M | +258.8% | +85.0% | 8.0% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Depreciation & Amortization | 16.36K | 112K | 839K | 1.02M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 609.82K | 3.53M | 10.24M | 18.86M |
| Change in Working Capital | 1.49M | 2.65M | (2.42M) | 3.5M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 856K | (346K) | 2.22M |
| Other Working Capital | 1.49M | 1.8M | (2.07M) | 1.29M |
| Other Non-Cash Items | 5.3M | 1.32M | 4.82M | 636K |
| Operating Cash Flow | (3.24M) | (27.18M) | (64.83M) | (87.47M) |
| Capital Expenditures | (284K) | (1.64M) | (2.41M) | (616K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (77.22M) | (380.74M) | (354.78M) |
| Sales of Investments | 0 | 0 | 209.8M | 167.93M |
| Other Investing Activities | (5M) | 0 | 3.21M | 0 |
| Investing Cash Flow | (5.28M) | (78.86M) | (170.14M) | (187.47M) |
| Debt Repayment | 7.9M | 0 | 0 | 0 |
| Common Stock Issued | 31.79M | 54K | 157.71M | 270.79M |
| Common Stock Repurchased | 0 | (4K) | 0 | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (134K) | 7K | 0 |
| Financing Cash Flow | 39.69M | 145.14M | 221.63M | 270.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.16M | 39.1M | (13.34M) | (4.16M) |
| Free Cash Flow | (3.53M) | (28.82M) | (67.23M) | (88.09M) |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.